Shubh Goel: What to expect from AstraZeneca at WCLC and ESMO

Shubh Goel, VP, US Franchise Head, ImmunoOncology and GI Tumors at AstraZeneca, shared a post on LinkedIn:

“This post is intended for a U.S. audience.

Our IO team has been on a hot streak the last few months, with positive study after positive study reading out in hard-to-treat tumor types. The next wave of IO data is on the horizon as our AstraZeneca team shares the latest research at the World Conference on Lung Cancer (WCLC) and the European Society of Medical Oncology (ESMO) starting next week.

At WCLC, we’re eager to show the promise of immunotherapy treatment in earlier stages of lung cancer, with the hope of transforming patient outcomes:
– Further data on event-free survival in the AEGEAN Phase III trial of perioperative treatment in resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC)

– Patient-reported outcomes from the ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy (CRT)

– Efficacy and safety data from the NeoCOAST2 Phase II platform trial evaluating multiple novel immunotherapy combinations before and after surgery in resectable, early-stage NSCLC

The following week at ESMO, we’ll showcase our advances in bladder and liver cancers, with an eye on challenging the current standards of care:
– A Presidential Symposium of the NIAGARA Phase III trial in patients with muscle-invasive bladder cancer (MIBC). After positive high-level data for both event-free and overall survival rates, we’re eagerly awaiting the full results of this peri-operative study in this hard-to-treat cancer.

– Five-year overall survival data from the HIMALAYA study in unresectable hepatocellular carcinoma. The HIMALAYA regimen continues to revolutionize treatment of unresectable HCC, delivering hope of unprecedented survival rates, and we’re committed to helping patients facing liver cancer to live even longer.

We’re building a legacy across lung, liver and bladder cancers to transform treatments while also leaning into new disease states. With each scientific discovery, we know there’s a patient who may benefit. We have the momentum in our pipeline and our portfolio to make a meaningful impact on patient communities – and we’re only getting started.

Learn more about AstraZeneca’s leadership at WCLC and ESMO 2024 here.”

Source: Shubh G./LinkedIn